drugset / Trial / NCT06919926

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926

RandomizedCrossoverQuadruple-blindTreatment

Summary

This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.

Timeline

Start
2025-04-17
Primary completion
2027-05
Completion
2028-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 220 mg

Indications